COX-2 and cancer: a new approach to an old problem.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Association between rs20417 polymorphism in cyclooxygenase-2 and gastric cancer susceptibility: Evidence from15 case-control studies.Medicine · 2019
   Pooled it
2. Cyclooxygenase-2 polymorphisms and susceptibility to gastric carcinoma: a meta-analysis.World journal of gastroenterology · 2010
   Pooled it
3. Therapeutic targeting of COX-2 in head and neck cancer: Mechanistic and clinical perspectives.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
   Review
4. In Silico and In Vitro Analyses of Strawberry-Derived Extracts in Relation to Key Compounds' Metabolic and Anti-Tumor Effects.International journal of molecular sciences · 2025
   Article
5. Cardioprotective Effects of Oroxylum indicum Extract Against Doxorubicin and Cyclophosphamide-Induced Cardiotoxicity.Cardiovascular toxicology · 2022
   Article
6. Biological Profile of TwoBiomolecules · 2021
   Article
7. A Systematic Review of the Cyclooxygenase-2 (COX-2) Expression in Rectal Cancer Patients Treated with Preoperative Radiotherapy or Radiochemotherapy.Journal of clinical medicine · 2021
   Review
8. Targeting COX-2 potently inhibits proliferation of cancer cellsTranslational cancer research · 2021
   Article
9. Targeting Lipid Peroxidation for Cancer Treatment.Molecules (Basel, Switzerland) · 2020
   Review
10. Genetic polymorphisms as non-modifiable susceptibility factors to laryngeal cancer.Bioscience reports · 2020
    Article
11. Anticancer therapeutics: a brief account on wide refinements.American journal of cancer research · 2020
    Review
12. Curcumol potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer.Oncotarget · 2017
    Article
13. The clinical significance of occult gynecologic primary tumours in metastatic cancer.Current oncology (Toronto, Ont.) · 2017
    Article
14. Cyclooxygenase-2 -1195G>A (rs689466) polymorphism and cancer susceptibility: an updated meta-analysis involving 50,672 subjects.International journal of clinical and experimental medicine · 2015
    Article
15. Immunohistochemical Analysis of Cyclooxygenase-2 in Non-Melanocytic Skin Cancer: Correlation With Morphological Subtype and Histologic Grade.World journal of oncology · 2014
    Article
16. Dioscorea japonica extract down-regulates prostaglandin E2 synthetic pathway and induces apoptosis in lung cancer cells.Journal of clinical biochemistry and nutrition · 2014
    Article
17. Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy.Biological research · 2014
    Article
18. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.Translational research : the journal of laboratory and clinical medicine · 2013
    Review
19. Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis.Critical reviews in oncology/hematology · 2013
    Review
20. Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.Translational research : the journal of laboratory and clinical medicine · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as